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LETTERS
Lung contusions and pandemic 
(H1N1) 2009 can cause ARDS (6,7). 
We do not know the relative role of 
each in causing the ARDS that our pa-
tient had, but the severity of clinical 
symptoms, although the lung injury 
was judged to be only of moderate 
magnitude, suggests that inﬂ  uenza 
played a major role in the develop-
ment of his acute lung disease. The 
infection with oseltamivir-resistant 
virus, for which he probably did not 
receive effective therapy, likely had an 
effect on the duration and severity of 
his course. 
Although our patient had a fa-
vorable outcome, the possibility of 
widespread resistance, similar to the 
phenomenon observed with seasonal 
inﬂ  uenza in the 2008–2009 season, is 
alarming and should be monitored. The 
suspicion of resistance should be based 
upon compatible clinical scenario, such 
as continuation of symptoms in spite of 
antiviral therapy (even in patients who 
are not immunocompromised), com-
bined with early performance of resis-
tance assays. Early and rapid detection 
of oseltamivir resistance and a change 
of antiviral treatment (if feasible) might 
beneﬁ  t the patient. 
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Human Infection 
with Lymphocytic 
Choriomeningitis 
Virus
To the Editor: I read with great 
interest the article regarding lympho-
cytic choriomeningitis virus (LCMV) 
meningitis in a New York City resident 
(1). The authors’ conclusion that there 
is a need to ascertain the true incidence 
of LCMV infection is worthy of under-
scoring. Nearly 15 years ago, in this 
same journal, we described congenital 
LCMV as an unrecognized teratogen 
and recommended further “research 
to deﬁ   ne the frequency of LCMV” 
(2). Five years later, we reiterated that 
recommendation when reporting ac-
quired LCMV meningoencephalitis in 
an adolescent from Tucson, Arizona 
(3). Despite, or because of, the lack of 
prospective studies, the fact that this 
author has accrued data regarding >60 
congenitally infected infants from all 
geographic areas in the United States 
during the past 15 years reinforces 
the concept that LCMV is a neglected 
pathogen whose time for more exten-
sive study has indeed come.
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Increasing 
Incidence of 
Nontuberculous 
Mycobacteria, 
Taiwan, 2000–2008 
To the Editor: Lai et al. (1) re-
ported an increase in the number of 
nontuberculous mycobacteria (NTM) 
isolates and patients with pulmonary 
NTM diseases after implementation of 
the BACTEC system (Becton Dickin-
son, Sparks, MD, USA) late in 2001. 
These authors also reported that the in-
crease was mainly in persons infected 
with Mycobacterium avium complex 
(MAC) and M. abscessus. They stated 
that diseases caused by NTM were 
deﬁ  ned according to current diagno-
sis criteria published in 2007 (2). This 
ﬁ  nding suggests that Lai et al. were 
able to review the clinical and radio-
logic information for all patients.
We wonder whether they were 
also able to identify and exclude peo-
ple with NTM colonization, i.e., per-
sons with positive cultures for NTM 
who did not meet the American Tho-
racic Society disease criteria. It would 
have been interesting to know the 
trend in colonized persons. In a previ-
ous study from British Columbia (3), 
we found an increase in the number of 
NTM isolates mostly in persons with 
MAC colonization. This ﬁ  nding coin-
cided with implementation of a new 
laboratory technique in 2000, which 
suggested that the new technology is 
more sensitive in detecting MAC. In 
contrast with the ﬁ   ndings of Lai et 
al., our study from British Columbia 
showed that the incidence in patients 
treated for NTM pulmonary disease 
(the group used as a surrogate of NTM 
disease) has been decreasing over 
time, which is reassuring.
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In Response: We thank Hernán-
dez-Garduño and Elwood for drawing 
attention to the issue of nontubercu-
lous mycobacteria (NTM) coloniza-
tion (1), which was not described in 
our study (2). Among 4,786 patients 
with NTM isolates treated at our hos-
pital during 2000–2008, colonization 
was found in 76.9% (3,681), and only 
23.1% (1,105) had NTM diseases ac-
cording to the criteria of the American 
Thoracic Society and Infectious Dis-
eases Society of America (3).
Annual proportions of NTM iso-
lates causing colonizations ranged 
from 29.2% in 2001 to 19.8% in 2007. 
During the study period, annual in-
cidences of NTM colonization and 
disease increased from 6.6/100,000 
inpatients and 2.7/100,000 outpatients 
in 2000 to 34.5/100,000 inpatients and 
10.2/100,000 outpatients in 2008. My-
cobacterium avium complex (MAC) 
was the most prevalent species, colo-
nizing 1,282 (34.8%) of 3,681 patients. 
Annual proportions of MAC isolates 
causing colonization ranged from 
20.0% in 2000 to 12.6% in 2006. An-
nual incidence of MAC colonization 
increased from 1.9/100,000 inpatients 
in 2000 to 12.3/100,000 inpatients 
in 2008; incidence of MAC disease 
also increased from 0.5/100,000 in-
patients in 2000 to 2.1/100,000 in-
patients in 2008. M. abscessus, the 
second most common species in our 
study (2), caused colonization and 
disease in 669 and 155 patients, re-
spectively. Annual incidence of M. 
abscessus colonization and infection 
also increased from 1.49/100,000 in-
patients and 0.3/100,000 outpatients 
in 2000 to 7.0/100,000 inpatients and 
1.9/100,000 outpatients in 2008.
Our study and a previous study 
in British Columbia (4) suggest that 
improvement in diagnostic methods 
would detect increased incidence of 
NTM, especially of MAC; most iso-
lates identiﬁ  ed in these studies were 
associated with colonization. We also 
demonstrated a gradual increase in the 
incidence of all NTM, MAC, and M. 
abscessus over time in Taiwan, which 
may be attributable to increasing vigi-
lance and awareness of these bacteria 
as human pathogens and the increased 
population of immunocompromised 
patients. Thus, clinicians should con-
sider diagnosing NTM diseases with 
sensitive and advanced laboratory 
methods because of the increasing 
population of patients at risk.
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